Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS (REGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Regeneron Pharmaceuticals : Sanofi beats profit forecasts, upbeat on prospects for eczema drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2017 | 10:30am CEST
A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris

PARIS (Reuters) - French drugmaker Sanofi's (>> Sanofi) profit beat forecasts in the first quarter and confirmed its earnings outlook for the year, lifting its shares on Friday.

PARIS (Reuters) - French drugmaker Sanofi's (>> Sanofi) profit beat forecasts in the first quarter and confirmed its earnings outlook for the year, lifting its shares on Friday.

The results were buoyed by Sanofi's speciality care division Genzyme, as well as vaccines and consumer products it has acquired from Germany's Boehringer Ingelheim.

Earlier this year, Sanofi had warned investors it expected 2017 earnings per share to be stable or slightly lower after its fourth quarter results were affected by an increase in taxes and one-off charges.

The company had also said in 2015 it was not targeting any 'meaningful' profit growth for two years, citing difficulties in its embattled diabetes division.

"Although it has now some margin to deliver actual numbers above guidance, Sanofi also has reasons to wait a bit more before raising it. Diabetes is still a very uncertain market segment to work in," Bryan Garnier analysts said in a note.

However, Sanofi, whose shares were up more than 2 percent at 0805 GMT, said it was confident Dupixent, a drug for moderate-to-severe atopic dermatitis that was approved in the United States at the end of last month, would sell well.

Analysts forecast annual Dupixent sales of more than $4 billion (£3.10 billion) by 2022, according to Thomson Reuters data. Developed with Regeneron (>> Regeneron Pharmaceuticals Inc), the drug is seen as the most important growth driver for the two companies, who have said Dupixent will have a list price of $37,000 a year.

Sanofi Chief Executive Olivier Brandicourt told journalists that he was "very encouraged with the early coverage" of Dupixent, adding that "the launch is delivering so far exactly on our expectations".

While the price of Dupixent before discounts and rebates to insurers is far more expensive than topical medicines and steroids used to treat eczema, it is less expensive than other injectable antibody drugs for serious skin conditions, such as psoriasis, that list for about $50,000 a year.

CONSUMER HEALTHCARE SHINES

Sanofi said on Friday first-quarter business net income rose 1 percent at constant exchange rates to 1.8 billion euros (£1.51 billion). Total sales rose 8.6 percent to 8.65 billion.

Analysts polled by Reuters in partnership with Inquiry Financial had on average been expecting business net profit of 1.6 billion euros and net sales of 8.38 billion.

Genzyme's sales were up 15.5 percent while revenue at the vaccines divisions rose 22.2 percent. Consumer healthcare products sales were up 42.7 percent.

Hurt by continued U.S. pricing pressure, diabetes and cardiovascular sales however suffered another downturn with revenue falling 7.7 percent.

(Additional reporting by Matthieu Protard; Editing by Leigh Thomas and Alexander Smith)

By Matthias Blamont

Stocks treated in this article : Sanofi, Regeneron Pharmaceuticals Inc
Stocks mentioned in the article
ChangeLast1st jan.
SANOFI -0.43% 65.31 Real-time Quote.-8.41%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
04/12REGENERON PHARMACEUTICALS : EMA to Review Cemiplimab as a Potential Treatment fo..
AQ
04/12FINDINGS ON PSORIASIS REPORTED BY IN : A Systematic Review)
AQ
04/11DIABETIC RETINOPATHY DRUG MARKET PRO : Global Diabetic Retinopathy Drug Market B..
AQ
04/09REGENERON PHARMACEUTICALS : to Report First Quarter 2018 Financial and Operating..
PR
04/06SANOFI : - EMA to review cemiplimab as a potential treatment for advanced cutane..
AQ
04/05SANOFI : - EMA to review Dupixent as potential treatment for inadequately contro..
AQ
04/04REGENERON PHARMACEUTICALS : EMA to Review DUPIXENT (dupilumab) as Potential Trea..
AQ
03/29REGENERON PHARMACEUTICALS : and Alnylam Pharmaceuticals Announce Collaboration t..
AQ
03/29REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Demonstrates Positive T..
AQ
03/26REGENERON PHARMACEUTICALS : and Alnylam Pharmaceuticals Announce Collaboration t..
AQ
More news
News from SeekingAlpha
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
04/18Catalyst Pipeline Portfolio Updates - Strong Start To For The Portfolio 
04/17Evelo Biosciences Files For U.S. IPO 
04/17Fixing Drug Costs 
04/11FDA OKs AI software to detect diabetic retinopathy 
Financials ($)
Sales 2018 6 389 M
EBIT 2018 2 477 M
Net income 2018 1 709 M
Finance 2018 3 045 M
Yield 2018 -
P/E ratio 2018 21,38
P/E ratio 2019 18,32
EV / Sales 2018 4,94x
EV / Sales 2019 4,19x
Capitalization 34 613 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 416 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Charles A. Baker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-14.19%34 613
GILEAD SCIENCES5.35%98 675
VERTEX PHARMACEUTICALS10.10%41 476
GENMAB22.84%12 876
BEIGENE LTD (ADR)73.08%9 059
BLUEBIRD BIO INC-1.88%8 735